CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

The purpose of this study is to determine the safety and tolerability of monotherapy CR-002 and to identify the MTD and/or optimal biologic dose and RP2D(s) in participants with locally advanced or metastatic solid tumors.

Trial Details

NCT ID
NCT07909031
Phase
PHASE1 / PHASE2
Sponsor
Crescent Biopharma, Inc.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • CR-002
Locations (sample)
  • Austin, Texas, United States|30.26715,-97.74306
  • Dallas, Texas, United States|32.78306,-96.80667
  • Fairfax, Virginia, United States|38.84622,-77.30637

Key Eligibility Criteria

  • Life expectancy ≥ 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
  • Adequate organ function and hematologic reserve based on laboratory parameters
  • Have measurable disease defined by RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →